Yelak Biru/LinkedIn
Jun 16, 2025, 16:24
Yelak Biru: Anito-Cel Drives Durable Responses in R/R Multiple Myeloma
Yelak Biru, President and Chief Executive Officer at International Myeloma Foundation, posted on X:
“Congratulations Dr. Kaur on this iMMagine-1 study result and presentation at EHA 2025
‘Anito-cel utilizes a novel, synthetic antigen-binding domain called the D-Domain, which allows for high transduction efficiency, CAR positivity, and CAR density on the T-cell surface. Coupled with a fast off rate and ability to detach from the BCMA target, [this provides] us with a safe and efficacious product,’ lead study author Gurbakhash Kaur said during the presentation.
-
Anito-cel achieved a 97% overall response rate in relapsed/refractory multiple myeloma patients with at least three prior therapies, with a stringent complete response rate of 68%.
-
The novel D-Domain in anito-cel enhances transduction efficiency and safety, contributing to its efficacy in the iMMagine-1 trial.
-
Safety data showed manageable cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome, with most cases resolving quickly.
-
Anito-cel is being further evaluated in the phase 3 iMMagine-3 trial against standard-of-care therapy for relapsed/refractory multiple myeloma.”
Title: Anito-Cel Drives Durable Responses in R/R Multiple Myeloma
Author: Chris Ryan
Read The Full Article at OncLive25.
Find More Posts on Hemostasis Today.
-
Sep 29, 2025, 12:54Microfluidic Technology Uncovers Ongoing TTP Disease Activity
-
Sep 29, 2025, 12:43Advancing Thrombosis Research: MRI-Based Methodology for Studying Thrombus Resolution
-
Sep 29, 2025, 05:58Samwel Mikaye on Understanding, Diagnosing, and Managing Deep Venous Thrombosis (DVT)
-
Sep 28, 2025, 14:08Mary Cushman: Dr Warkentin Is a Giant in Hematology
-
Sep 28, 2025, 13:31Michael Makris Highlights Vaccine Misinformation and Its Risks
-
Sep 29, 2025, 12:33Allison Wheeler: Some Days I Love Science a Little Bit More
-
Sep 29, 2025, 06:23Yudi Hardianto and Colleagues Give a Review on Stroke Rehabilitation in LMICs
-
Sep 29, 2025, 04:42Wolfgang Miesbach on the Bi8 Study: A Novel FVIII-Mimetic Antibody Gene Therapy for Haemophilia A
-
Sep 29, 2025, 04:16Salvador Payán Pernía on Equity Challenges in Access to Gene Therapy for Hemoglobinopathies
-
Sep 29, 2025, 04:02Nicolas Gendron: A Very Nice Demonstration by The Authors - Coffee is Associated with Reduced Risk of VTE
-
Sep 29, 2025, 05:06Sue Bacon on the Importance of Addressing Hospital-Acquired DVT and PE
-
Sep 24, 2025, 11:06Wolfgang Miesbach Reports Promising Results for New Subcutaneous von Willebrand Disease Therapy VGA039
-
Sep 23, 2025, 06:40Richard Buka: CSL Behring Have Announced a Collaboration with Dutch Biotech, VarmX
-
Sep 22, 2025, 07:10Aspirin Beyond the Heart․ Targeting PI3K-Altered Colorectal Cancer
-
Sep 22, 2025, 06:04ClearPlasma: A New Filter Technology to Enhance Clot Stability in Donated Plasma
-
Sep 29, 2025, 07:02Kambua Manundu: We Walked to Protest the Countless Lives of Women We Have Lost to Post Partum Hemorrhage
-
Sep 29, 2025, 06:41Ouma Oluga Unveiled Plans to Make Sickle Cell Screening Mandatory in Kenya at 80th UN General Assembly
-
Sep 29, 2025, 04:51Nathan Connell on Breakthrough Gene Therapy Advancing Care for People with Hemophilia
-
Sep 29, 2025, 04:28Emmeran Hauser: Fantastic to See First Results of Our Work in Europe
-
Sep 28, 2025, 10:33Côme Bommier: Burnout Is Common Among Hematology Professionals
Sep 29, 2025, 12:54
Sep 29, 2025, 12:33
Sep 29, 2025, 06:23
Sep 29, 2025, 05:06
Sep 29, 2025, 04:28